Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05825625 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv5
  2. Primary completion date: Nov 1, 2029 to Dec 1, 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Feb 1, 2030 to Jun 1, 2027
    • Site details revised at 2 of 2 sites
    v4
  3. Study sites: 1 to 2
    • Eligibility criteria expanded, about 2 words
    v3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of May 1, 2023 to May 26, 2023
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Prospective, non-randomized, open-label, single-arm phase II trial to investigate the feasibility and efficacy of combining chemotherapy with tiragolumab and atezolizumab as neoadjuvant and adjuvant treatment for surgical NSCLC patients.
Trial Details
NCT Number NCT05825625
Lead Sponsor Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Collaborators: Thoraxklinik-Heidelberg gGmbH, Roche Pharma AG
Conditions
(from sponsor)		 Non-small Cell Lung Cancer
Related terms Carcinoma, Non-Small-Cell Lung
Enrollment 35 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov